– Special EnChroma Glasses Allow Color Blind Fathers to See Colors in Acclaimed Exhibits in San Francisco & Chicago – CHICAGO & SAN FRANCISCO–(BUSINESS WIRE)–#artofthebrick—EnChroma – creators of glasses for color blindness – and The Art of the Brick, the world’s most popular display of LEGO® art – today announced that EnChroma glasses will be … [Read more…]
Innovative technology platform detects loneliness and connects users with critical resources that can help improve health and lives. AUSTIN, Texas–(BUSINESS WIRE)–#Amerigroup–Amerigroup, one of Texas’ largest coordinators of managed healthcare benefits, and Pyx Health, a tech-enabled services company, are working together to combat loneliness and social isolation across Texas. The organizations are offering Texans an innovative … [Read more…]
Improving practice efficiency and patient care with Asana Smiles™ for Align, a workflow with HIPAA compliant features SAN FRANCISCO–(BUSINESS WIRE)–Today Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), a leading work management platform for teams, announced a new strategic partnership with Align Technology, a leading global medical device company that designs, manufactures, and sells the Invisalign system of … [Read more…]
CHICAGO–(BUSINESS WIRE)–Adtalem Global Education (NYSE: ATGE), a leading healthcare educator, has appointed Michael Betz as president, Walden University, effective immediately. In his role, Betz is responsible for the strategy and operations of Walden with a mandate to further enhance Walden’s position as a leading innovator in distance learning while maintaining its commitment to expanding access … [Read more…]
LAS VEGAS–(BUSINESS WIRE)–$NASDAQ #Biotechnology–PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites. The initiation … [Read more…]
ENHERTU data from historic DESTINY-Breast04 trial in patients with HER2 low metastatic breast cancer has the potential to redefine how breast cancer is categorized and treated First presentation of DS-6000 and new patritumab deruxtecan results further support the strength of Daiichi Sankyo’s DXd ADC technology across multiple cancers including breast, lung, ovarian and renal cell … [Read more…]
A leader in outpatient imaging services to provide smart digital and self-service experiences with NICE CXone to improve services for patients, health systems and hospitals HOBOKEN, N.J.–(BUSINESS WIRE)–#NICE—NICE (Nasdaq: NICE) today announced that MedQuest Associates, a leading manager of outpatient diagnostic imaging facilities, has selected the NICE CXone Essentials Suite to enrich its services to … [Read more…]
ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, has been recognised with … [Read more…]
– Lead Clinical Candidate, JK07, Demonstrates Favorable Safety and Further Promising Activity in Cohort 2 of Phase 1b Heart Failure with Reduced Ejection Fraction Study; Enrollment in Cohort 3 Now Ongoing – – Clinical Trial Application Submitted in Europe for Lead Oncology Program JK08, the first CTLA-4/IL-15 Antibody Fusion Protein, for the Treatment of Solid … [Read more…]
ENHERTU® (fam-trastuzumab deruxtecan-nxki) data will show the potential to improve survival for metastatic breast cancer patients and define a new segment of HER2-low disease Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca advances its ambition to redefine cancer care … [Read more…]
